Mark T. Iwicki - Jan 4, 2024 Form 4 Insider Report for KALA BIO, Inc. (KALA)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Eric Trachtenberg, Attorney-in-Fact
Stock symbol
KALA
Transactions as of
Jan 4, 2024
Transactions value $
-$30,547
Form type
4
Date filed
1/5/2024, 04:04 PM
Previous filing
Jun 27, 2023
Next filing
Mar 27, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KALA Common Stock Award $0 +14.3K +5.17% $0.00 291K Jan 4, 2024 Direct F1, F2
transaction KALA Common Stock Sale -$30.5K -4.54K -1.56% $6.73 286K Jan 4, 2024 Direct F3, F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALA Stock Option (right to buy) Award $0 +64.5K $0.00 64.5K Jan 4, 2024 Common Stock 64.5K $7.00 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with the Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2025, as to 1/3 of the shares underlying the RSUs on January 4, 2026 and as to the final 1/3 of shares underlying the RSUs on January 4, 2027.
F2 Includes 287,095 unvested RSUs.
F3 This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs granted on January 4, 2023 and January 4, 2021.
F4 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.73 to $6.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F5 Includes 272,690 unvested RSUs.
F6 This option was granted on January 4, 2024 and vests over four years beginning on the vesting commencement date of January 4, 2024, with 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter until January 4, 2028, subject to the Reporting Person's continued employment with the Issuer.